Download PDF

1. Company Snapshot

1.a. Company Description

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases.The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases.Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program.


The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases.It has a research collaboration agreement with Janssen Pharmaceuticals, Inc.to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology.


MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.

Show Full description

1.b. Last Insights on MGTX

MeiraGTx Holdings plc's recent performance was driven by several positive factors. The company's Q4 earnings beat estimates, with quarterly earnings of $0.19 per share, surpassing the Zacks Consensus Estimate of a loss of $0.6 per share. Additionally, the company received FDA Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 radiation-induced xerostomia. MeiraGTx also announced positive three-year data from the Phase 1 AQUAx clinical study of AAV-hAQP1. Furthermore, the company acquired botaretigene sparoparvovec for the treatment of X-linked retinitis pigmentosa. (Source: MeiraGTx Holdings plc, March 26, 2026)

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

MeiraGTx Announces Pricing of $100 Million Offering of Ordinary Shares

11:47

Source: globenewswire.com

Card image cap

MeiraGTx Announces the Acquisition of Botaretigene Sparoparvovec (bota-vec) for the Treatment of X-linked Retinitis Pigmentosa (XLRP)

11:10

Source: globenewswire.com

Card image cap

MeiraGTx Announces Positive Three-year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Late Radiation-Induced Xerostomia

11:00

Source: globenewswire.com

Card image cap

MeiraGTx: Turning Dry Mouth Into Liquid Gold

Apr -15

Source: seekingalpha.com

Card image cap

MeiraGTx to Present 3-Year Data from the Phase 1 AQUAx Clinical Study of AAV-hAQP1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia on Thursday, April 16, 2026

Apr -14

Source: globenewswire.com

Card image cap

Strength Seen in MeiraGTx (MGTX): Can Its 6.2% Jump Turn into More Strength?

Mar -31

Source: zacks.com

Card image cap

MeiraGTx Holdings plc (MGTX) Presents at RBC Capital Markets Virtual Ophthalmology Conference Transcript

Mar -27

Source: seekingalpha.com

Card image cap

Alexandria Forbes Sells 62,000 Shares of MeiraGTx (NASDAQ:MGTX) Stock

Mar -27

Source: defenseworld.net

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (9.03%)

6. Segments

Retinal Drugs and Gene Therapies

Expected Growth: 9.03%

MeiraGTx Holdings plc's Retinal Drugs and Gene Therapies segment growth is driven by increasing prevalence of inherited retinal diseases, advancements in gene therapy technology, and strong clinical trial results. Growing demand for novel treatments, strategic partnerships, and expanding product pipeline also contribute to the 9.03% growth.

7. Detailed Products

AAV-RPGR

Gene therapy for the treatment of X-linked retinitis pigmentosa

AAV-CNGB3

Gene therapy for the treatment of achromatopsia

AAV-RHO

Gene therapy for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa

AAV-ND4

Gene therapy for the treatment of Leber hereditary optic neuropathy

AAV-GAD

Gene therapy for the treatment of Parkinson's disease

AAV-FLT1

Gene therapy for the treatment of wet age-related macular degeneration

8. MeiraGTx Holdings plc's Porter Forces

Forces Ranking

Threat Of Substitutes

MeiraGTx Holdings plc operates in the biotechnology industry, which is characterized by high research and development costs. While there are substitutes available, they are not easily accessible, and the company's products are differentiated, reducing the threat of substitutes.

Bargaining Power Of Customers

MeiraGTx Holdings plc's customers are primarily pharmaceutical companies and research institutions, which have limited bargaining power due to the company's specialized products and services.

Bargaining Power Of Suppliers

MeiraGTx Holdings plc relies on a few key suppliers for raw materials and equipment, giving them some bargaining power. However, the company's specialized products and services reduce the suppliers' negotiating power.

Threat Of New Entrants

The biotechnology industry is highly competitive, and new entrants can easily disrupt the market. MeiraGTx Holdings plc's intellectual property and specialized products provide some barriers to entry, but new entrants can still pose a significant threat.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. MeiraGTx Holdings plc faces intense competition from companies with similar products and services.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 35.58%
Debt Cost 10.48%
Equity Weight 64.42%
Equity Cost 10.48%
WACC 10.48%
Leverage 55.23%

11. Quality Control: MeiraGTx Holdings plc passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Relay Therapeutics

A-Score: 4.6/10

Value: 6.9

Growth: 6.8

Quality: 3.8

Yield: 0.0

Momentum: 8.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
MeiraGTx

A-Score: 4.2/10

Value: 8.0

Growth: 2.6

Quality: 4.2

Yield: 0.0

Momentum: 7.5

Volatility: 2.7

1-Year Total Return ->

View Full Report
Stock-Card
Foghorn Therapeutics

A-Score: 3.9/10

Value: 8.0

Growth: 5.4

Quality: 6.0

Yield: 0.0

Momentum: 2.5

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Aadi Bioscience

A-Score: 3.8/10

Value: 8.0

Growth: 5.4

Quality: 4.0

Yield: 0.0

Momentum: 2.5

Volatility: 3.0

1-Year Total Return ->

View Full Report
Stock-Card
Ginkgo Bioworks

A-Score: 3.7/10

Value: 8.6

Growth: 3.3

Quality: 4.5

Yield: 0.0

Momentum: 4.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Sutro Biopharma

A-Score: 3.2/10

Value: 9.6

Growth: 2.2

Quality: 6.1

Yield: 0.0

Momentum: 0.5

Volatility: 0.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

9.2$

Current Price

9.2$

Potential

-0.00%

Expected Cash-Flows